Announced
Completed
Financials
Tags
Acquisition
Private
Pharmaceuticals
Majority
Friendly
pharmaceutical company
United States
Cross Border
Single Bidder
Completed
Synopsis
Santen Holdings, a wholly-owned subsidiary of Santen Pharmaceutical, a producer and distributor of ophthalmic medicine, completed the acquisition of Eyevance Pharmaceuticals, a pharmaceutical company, for $225m. "We're very pleased to have entered into this agreement. Through this purchase, we will quickly establish a business base in the U.S. and both humbly face and further contribute to the needs of a greater number of patients by offering more value. At the same time, we will accelerate global business rollout by gaining access to the U.S. and our presence in the market, aiming for even further corporate growth and contribution to ophthalmic treatments for people around the world.," Shigeo Taniuchi, Santen President and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.